A Phase 3 interventional study of Evolocumab in Dyslipidemia, sponsored by Amgen. Completed at 198 sites in 7 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-04-07.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing evolocumab in Dyslipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Dyslipidemias.
Among the 10 studies testing evolocumab in Dyslipidemias, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 6th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 10 studies testing evolocumab in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,035 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 409 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing evolocumab in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
This is a multicenter, open-label extension study designed to assess the long-term safety of evolocumab in subjects who completed the FOURIER study,which is a randomized placebo-controlled study of evolocumab in subjects with clinically evident atherosclerotic CVD on stable effective statin therapy. Eligible subjects at sites participating in FOURIER OLE who have signed the FOURIER OLE informed consent may be enrolled at the completion of FOURIER study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects are randomized to a single arm and will receive evolocumab 140mg every two weeks (Q2W) or 420mg monthly (QM) according to subject's preference.
Biological: Evolocumab
subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Number of Participants Who Experienced an Adverse Event
All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.
Time frame: Up to 5 years
Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit
Time frame: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
Percentage of Participants Who Achieved an LDL-C Level < 40 mg/dL
Time frame: Week 12, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, Week 192, Week 216, Week 260
This was an open-label extension of study 20110118 (NCT01764633). Eligible participants were enrolled after the completion of the 20110118 study. 5035 participants were enrolled at 195 centers in Czech Republic, Hungary, Poland, Russia, Slovakia, Ukraine, and the United States from 02 September 2016 to 17 March 2022.
| Milestone | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study |
|---|---|---|
| Started | 2535 | 2500 |
| Completed | 2084 | 2090 |
| Not completed | 451 | 410 |
| Withdrew: Withdrawal by subject | 57 | 56 |
| Withdrew: Decision by sponsor | 7 | 7 |
| Withdrew: Lost to follow-up | 91 | 78 |
| Withdrew: Missing | 2 | 1 |
| Withdrew: Death | 294 | 268 |
All adverse event summaries for the primary analysis of the primary endpoint (OLE study period only) included all treatment-emergent events reported on the Event electronic case report form (eCRF), including CEC positively reviewed events and disease-related events.
| Participants | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event | 2144 | 2084 |
| Percent Change | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study |
|---|---|---|
| Week 12 | -55.93 ± 33.73 | -58.43 ± 30.64 |
| Week 24 | -56.69 ± 33.58 | -58.38 ± 31.52 |
| Week 48 | -58.52 ± 33.66 | -59.05 ± 33.06 |
| Week 72 | -56.35 ± 33.73 | -56.90 ± 33.14 |
| Week 96 | -55.70 ± 33.72 | -56.62 ± 33.36 |
| Week 120 | -53.37 ± 36.77 | -54.89 ± 35.99 |
| Week 144 | -56.96 ± 32.82 | -57.38 ± 32.34 |
| Week 168 | -56.49 ± 37.04 | -58.22 ± 34.60 |
| Week 192 | -57.42 ± 35.43 | -58.81 ± 33.27 |
| Week 216 | -54.68 ± 35.53 | -57.11 ± 32.89 |
| Week 260 | -53.69 ± 37.51 | -56.63 ± 36.14 |
| Percentage of Participants | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study |
|---|---|---|
| Week 12 | 58.7 (56.7 to 60.6) | 61.4 (59.4 to 63.3) |
| Week 24 | 60.2 (58.2 to 62.1) | 61.6 (59.7 to 63.5) |
| Week 48 | 61.7 (59.8 to 63.7) | 61.9 (60.0 to 63.9) |
| Week 72 | 59.7 (57.7 to 61.7) | 58.5 (56.5 to 60.5) |
| Week 96 | 57.3 (55.3 to 59.3) | 59.9 (57.8 to 61.9) |
| Week 120 | 54.6 (52.5 to 56.6) | 56.4 (54.4 to 58.5) |
| Week 144 | 59.6 (57.6 to 61.7) | 60.4 (58.3 to 62.4) |
| Week 168 | 60.9 (58.8 to 63.0) | 61.5 (59.4 to 63.5) |
| Week 192 | 61.8 (59.4 to 64.1) | 62.3 (59.9 to 64.7) |
| Week 216 | 56.0 (53.6 to 58.3) | 59.2 (56.9 to 61.5) |
| Week 260 | 56.9 (54.6 to 59.1) | 59.2 (56.9 to 61.4) |
Collected over Day 1 up to approximately 5 years during the OLE study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo in Parent Study | 309/2,535 (12.2%) | 1,077/2,532 (42.5%) | 956/2,532 (37.8%) |
| Evolocumab in Parent Study | 287/2,500 (11.5%) | 1,045/2,499 (41.8%) | 959/2,499 (38.4%) |
| Event | Placebo in Parent Study | Evolocumab in Parent Study |
|---|---|---|
| PneumoniaInfections and infestations | 50/2532 | 74/2499 |
| Acute myocardial infarctionCardiac disorders | 74/2532 | 52/2499 |
| Atrial fibrillationCardiac disorders | 57/2532 | 47/2499 |
| Angina pectorisCardiac disorders | 56/2532 | 52/2499 |
| Angina unstableCardiac disorders | 49/2532 | 37/2499 |
| Cardiac failureCardiac disorders | 46/2532 | 44/2499 |
| Coronary artery diseaseCardiac disorders | 41/2532 | 30/2499 |
| Cardiac failure congestiveCardiac disorders | 37/2532 | 40/2499 |
| Non-cardiac chest painGeneral disorders | 26/2532 | 37/2499 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 37/2532 | 36/2499 |
| Event | Placebo in Parent Study | Evolocumab in Parent Study |
|---|---|---|
| HypertensionVascular disorders | 327/2532 | 355/2499 |
| Upper respiratory tract infectionInfections and infestations | 208/2532 | 162/2499 |
| BronchitisInfections and infestations | 162/2532 | 173/2499 |
| NasopharyngitisInfections and infestations | 157/2532 | 156/2499 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 144/2532 | 138/2499 |
| Diabetes mellitusMetabolism and nutrition disorders | 139/2532 | 135/2499 |
| Back painMusculoskeletal and connective tissue disorders | 133/2532 | 137/2499 |
The Overall Number of Baseline Participants is made up of all of the participants that received study drug.
| Age, Continuous(Years) | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Total |
|---|---|---|---|
| Mean | 62.3 ± 8.4 | 62.4 ± 8.5 | 62.3 ± 8.4 |
| Sex: Female, Male(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Total |
|---|---|---|---|
| Female | 638 | 622 | 1260 |
| Male | 1894 | 1877 | 3771 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Total |
|---|---|---|---|
| Hispanic or Latino | 55 | 63 | 118 |
| Not Hispanic or Latino | 2477 | 2436 | 4913 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 2 | 7 |
| Asian | 9 | 21 | 30 |
| Black or African American | 111 | 117 | 228 |
| Native Hawaiian or Other Pacific Islander | 5 | 4 | 9 |
| White | 2392 | 2345 | 4737 |
| Multiple | 4 | 4 | 8 |
| Other | 6 | 6 | 12 |
Showing the first 100 of 198 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2016 to primary completion in Mar 2022, 66 months.
Results were first posted in Feb 2023, 11 months after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 66 months is above that.
Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab